Late breaker poster

 General hepatology

Poster Area
English
Poster session
11 April 2019 09:00 - 17:00


Presentations

LBP-01 In NAFLD, alcohol drinking habits and genetics predict progression to advanced liver disease: follow-up of population surveys
Fredrik Åberg - Sweden
11 April 2019 09:00 - 17:00

Abstract
LBP-02 Association between HBsAg loss and long-term clinical outcome in chronic hepatitis B: a systematic review and meta-analysis analysis
Ryan Anderson - United States
11 April 2019 09:00 - 17:00

Abstract
LBP-03 LPCN 1144, an Androgen Receptor Agonist Targeted for NASH, Reduces Liver Fat and Key Serum Biomarkers
Jonathan Baker - United States
11 April 2019 09:00 - 17:00

Abstract
LBP-04 Investigation of synbiotic treatment in non alcoholic fatty liver disease (NAFLD): Results of the INSYTE study
Chris Byrne - United Kingdom
11 April 2019 09:00 - 17:00

Abstract
LBP-05 classification and mutation prediction based on liver cancer hisopathological images using deep learning
Mingyu Chen - China
11 April 2019 09:00 - 17:00

Abstract
LBP-06 High Seroprotection Rates Achieved with Two Doses of Sci-B-Vac, a Third Generation Hepatitis B vaccine containing PreS1, PreS2 and S Antigens.
Francisco Diaz-Mitoma - Canada
11 April 2019 09:00 - 17:00

Abstract
LBP-07 Association of pharmacogenomics and pharmacokinetics with antiviral activity of Pradefovir for treatment of chronic hepatitis B infection
yanhua ding
11 April 2019 09:00 - 17:00

Abstract
LBP-08 The World's Largest Hepatitis C Screening Program in Egypt
Magdi El-Serafy - Egypt
11 April 2019 09:00 - 17:00

Abstract
LBP-09 Liver humanization of Fah -/- /Rag2 -/- /Il2rg -/- NOD mice with human hepatocytes homozygous for M148I PNPLA3 allows the assessment of specific genotype contribution to NASH development in vivo.
Lander Foquet - United States
11 April 2019 09:00 - 17:00

Abstract
LBP-10 A structurally engineered fatty acid, icosabutate, rapidly normalises elevated plasma ALT and gamma-glutamyl transferase (GGT) concentrations in a study population at high risk of NAFLD/NASH
David A. Fraser - Netherlands
11 April 2019 09:00 - 17:00

Abstract
LBP-11 Is it possible to successfully link migrants from low-income countries to HBV, HCV, and HIV services upon arrival in the European Union?
Jeffrey Lazarus - Spain
11 April 2019 09:00 - 17:00

Abstract
LBP-12 Phase 1a Study of the Safety, Tolerability and Pharmacokinetics of ABI-H2158, a Novel Second-Generation HBV Core Inhibitor, in Healthy Volunteers
Edward Gane - New Zealand
11 April 2019 09:00 - 17:00

Abstract
LBP-13

Effect of treatment of hepatitis B patients with tenofovir disoproxil or entecavir on risk of hepatocellular cancer death in a U.S. Cohort


Stuart C Gordon - United States
11 April 2019 09:00 - 17:00

Abstract
LBP-14 Magnetic Resonance Biomarkers for Early Phase Steatohepatitis Clinical Trials: Short Term Evaluation in Adolescents, Transitoriness or Stability in Steatosis (STEATOSIS)
Nidhi Goyal - United States
11 April 2019 09:00 - 17:00

Abstract
LBP-15 Urinary Liver Fatty-Acid-Binding Protein (uL-FABP) improves accuracy of MELD score to predict short-term mortality in patients with decompensated cirrhosis
Adria Juanola - Spain
11 April 2019 09:00 - 17:00

Abstract
LBP-16 Phase II trial to evaluate immunogenicity and safety of a new adjuvanted HBAI20 Hepatitis B vaccine in non-responders: BE RESPONDER.
Özgür Koc - Belgium
11 April 2019 09:00 - 17:00

Abstract
LBP-17 Robust Mucosal-associated invariant T (MAIT) cell activation in response to interactions with primary human liver cell subsets
Martin Lett - Switzerland
11 April 2019 09:00 - 17:00

Abstract
LBP-18 Effect of Obeticholic Acid on Liver Function in Patients with Fibrosis due to NASH
Naim Alkhouri - United States
11 April 2019 09:00 - 17:00

Abstract
LBP-19 NGM282 Promotes HDL Biogenesis and Transhepatic Cholesterol Efflux to Prevent Atherosclerosis in Mice
Lei Ling - United States
11 April 2019 09:00 - 17:00

Abstract
LBP-20 VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial
Rohit Loomba - United States
11 April 2019 09:00 - 17:00

Abstract
LBP-21 Effect of NGM282, an FGF19 Analogue, on Pruritus in Patients with Primary Sclerosing Cholangitis: Analysis of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Marlyn J. Mayo - United States
11 April 2019 09:00 - 17:00

Abstract
LBP-22 Outcome of 119 cirrhotic patients with splanchnic thrombosis: a single center real-life experience
Giorgia Micucci - Italy
11 April 2019 09:00 - 17:00

Abstract
LBP-23 Prognostic Impact of Peritumoral Neutrophil Infiltration on Hepatocellular Carcinoma Recurrence Following Liver Transplantation.
Marc Najjar - United States
11 April 2019 09:00 - 17:00

Abstract
LBP-24 Safety, tolerability and efficacy of volixibat, an apical sodium-dependent bile acid transporter inhibitor, in adults with non-alcoholic steatohepatitis: 24-week interim analysis results from a phase 2 study
Philip Newsome - United Kingdom
11 April 2019 09:00 - 17:00

Abstract
LBP-25 a phase 1 clinical trial of therapeutic vaccine t101 in chronic hepatitis b(chb) patients: a randomized, double-blind, placebo-controlled, single and multiple injections, dose escalation study
Junqi Niu - China
11 April 2019 09:00 - 17:00

Abstract
LBP-26 Magnetically controlled capsule endoscopy as a noninvasive tool for risk stratification of gastroesophageal varices in compensated cirrhosis (CHESS1801): A prospective multicenter study
Xiaolong Qi - China
11 April 2019 09:00 - 17:00

Abstract
LBP-27 Preliminary analysis of SuperDOT-C: A cluster randomised controlled trial of pharmacy-led versus conventional treatment for HCV positive patients receiving daily opioid substitution therapy - The Tayside sites
Andrew Radley - United Kingdom
11 April 2019 09:00 - 17:00

Abstract
LBP-29 BIO89-100, a novel PEG-FGF21 analogue, is efficacious following weekly and every 2-week subcutaneous dosing in spontaneous diabetic cynomolgus monkeys
Moti Rosenstock - Israel
11 April 2019 09:00 - 17:00

Abstract
LBP-30 Changes in Serum Bile Acids Correlate with 7alpha-Hydroxy-4-Cholesten-One and Fibrogenesis Biomarker Pro-C3 with NGM282 Therapy in Patients with Nonalcoholic Steatohepatitis
Arun Sanyal - United States
11 April 2019 09:00 - 17:00

Abstract
LBP-31 AXA1665, a novel composition of amino acids restores the dysregulated amino acid profile, lowers ammonia, and improves body composition and function in Child-Pugh class A and B subjects
Manu Chakravarthy - United States
11 April 2019 09:00 - 17:00

Abstract
LBP-32 The Natural History of Ferroportin Disease – First Results of the International, Multicenter EASL non-HFE Registry
Benedikt Schaefer - Austria
11 April 2019 09:00 - 17:00

Abstract
LBP-33 Gelesis superabsorbent hydrogel prevents hepatic steatosis in a high fat diet-induced NAFLD pre-clinical model
Elaine Chiquette - United States
11 April 2019 09:00 - 17:00

Abstract
LBP-34 Effect of Resistance Associated Substitutions on Retreatment of HCV infected patients with prior failure to Direct Acting Antiviral Therapy
David Smith - United Kingdom
11 April 2019 09:00 - 17:00

Abstract
LBP-35 Kupffer cell development: A link between Notch signaling and LXRα
Wouter T'Jonck - Belgium
11 April 2019 09:00 - 17:00

Abstract
LBP-36 Inhibition of glutamine synthetase in monocytes from patients with Acute-on-Chronic Liver Failure resuscitates their antibacterial and inflammatory capacity
Schalk van der Merwe - Belgium
11 April 2019 09:00 - 17:00

Abstract
LBP-37 Evaluation of Hepatitis C Virus Rapid Diagnostic Test in HCV mono- and HCV/HIV co-infected patients from Low and Middle Income Countries
Beatrice Vetter - Switzerland
11 April 2019 09:00 - 17:00

Abstract
LBP-38 Increasing Number of Metabolic Co-Morbidities are Associated with Higher Risk of Advanced Fibrosis in Patients with Nonalcoholic Steatohepatitis
Robert Wong - United States
11 April 2019 09:00 - 17:00

Abstract
LBP-40 Development of Oligonucleotide-Based miR-132 Antagonists for the Treatment of NASH
Shoutian Zhu - United States
11 April 2019 09:00 - 17:00

Abstract